FMP

FMP

Enter

PLUR - Pluri Inc.

Financial Summary of Pluri Inc.(PLUR), Pluri Inc., a biotechnology company, focuses on the development of placenta-based cell therapy produ

photo-url-https://financialmodelingprep.com/image-stock/PLUR.png

Pluri Inc.

PLUR

NASDAQ

Pluri Inc., a biotechnology company, focuses on the development of placenta-based cell therapy product candidates for the treatment of multiple inflammatory, muscle injuries, and hematologic conditions. The company develops placental expanded (PLX) based cell therapy products, including PLX-PAD that is in Phase III clinical trials for the muscle recovery after surgery for hip fracture; in Phase II clinical trails for the treatment of acute respiratory distress syndrome associated with COVID-19; and in Phase I/II clinical trial for treatment of steroid-refractory graft versus host disease. It also develops PLX-R18 for incomplete hematopoietic recovery following hematopoietic cell transplantation, as well as a solution for the treatment of acute radiation syndrome. The company was formerly known as Pluristem Therapeutics Inc. and changed its name to Pluri Inc. in July 2022. Pluri Inc. was incorporated in 2001 and is based in Haifa, Israel.

5.09 USD

0.09 (1.77%)

About

ceo

Mr. Yaacov Yanay

sector

Healthcare

industry

Biotechnology

website

https://pluri-biotech.com/

exchange

NASDAQ

Description

Pluri Inc., a biotechnology company, focuses on the development of placenta-based cell therapy product candidates for the treatment of multiple inflammatory, muscle injuries, and hematologic conditions. The company develops placental expanded (PLX) based cell therapy products, including PLX-PAD that is in Phase III clinical trials for the muscle recovery after surgery for hip fracture; in Phase II clinical trails for the treatment of acute respiratory distress syndrome associated with COVID-19; and in Phase I/II clinical trial for treatment of steroid-refractory graft versus host disease. It also develops PLX-R18 for incomplete hematopoietic recovery following hematopoietic cell transplantat...

CIK

0001158780

ISIN

US72942G1040

CUSIP

72942G104

Address

Building No. 5

Phone

972 7 4710 8600

Country

IL

Employee

123

IPO Date

Jun 30, 2003

Summary

CIK

0001158780

Exchange

NASDAQ

Industry

Biotechnology

Sector

Healthcare

CUSIP

72942G104

ISIN

US72942G1040

Country

IL

Price

5.09

Beta

1.51

Volume Avg.

27.76k

Market Cap

26.39M

Shares

-

52-Week

3.44-8.56

DCF

-0.69

ROE

-

ROA

-

Operating Margin

-

Debt/Equity

-

P/E

-1.1

P/B

-

Website

https://pluri-biotech.com/

Historical Prices

We are unable to load the chart at this time.

fmp-logo

Financial Statement

We are unable to load the chart at this time.

fmp-logo

Earnings

We are unable to load the chart at this time.

fmp-logo

Upgrades and Downgrades

We are unable to load this data!

fmp-logo

People Also Watch

page loading card

Latest PLUR News

It looks like there's no news available.

fmp-logo
FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedinfacebookinstagram
2017-2024 © Financial Modeling Prep